Navigating the Maze: Challenges & Strategies for Combination Immunotherapies in Early-Phase Clinical Trials
Time: 9:00 am
day: Day One
Details:
• Achieving impressive monotherapy efficacy in late lines/post PDx pts has a very low likelihood
• The true value of an IO agent resides in adding clinical benefit on top of standard of care or rational combo with new agents
• How to select and assess cancer immunotherapy combinations in early-phase clinical studies (based upon rational mechanism of action concurrent to standard of care landscape (bolt – on , 3 vs 2, etc.)
